Published in J Am Soc Hypertens on June 03, 2009
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation (2011) 2.52
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol (2012) 1.60
Liraglutide. Nat Rev Drug Discov (2010) 1.27
Cardiovascular effects of gliptins. Nat Rev Cardiol (2013) 1.23
Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res (2012) 1.17
Understanding the cardiovascular effects of incretin. Diabetes Metab J (2011) 1.01
Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care (2013) 0.95
Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice. PLoS One (2012) 0.90
A Generic Integrated Physiologically based Whole-body Model of the Glucose-Insulin-Glucagon Regulatory System. CPT Pharmacometrics Syst Pharmacol (2013) 0.87
Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res (2012) 0.86
Linagliptin: from bench to bedside. Drug Des Devel Ther (2014) 0.86
Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther (2015) 0.85
Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria. Int J Endocrinol (2013) 0.85
The role of the Wnt signaling pathway in incretin hormone production and function. Front Physiol (2012) 0.84
Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents. Nephrol Dial Transplant (2015) 0.82
Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Ther Adv Endocrinol Metab (2013) 0.80
Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. Circulation (2014) 0.78
Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-κB pathway. Acta Pharmacol Sin (2013) 0.77
Metalloproteinases: key and common mediators of multiple GPCRs and candidate therapeutic targets in models of hypertensive cardiac disease. Drug Discov Today Dis Models (2012) 0.77
Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity Intima-Media Thickness in Type 2 Diabetic Patients. High Blood Press Cardiovasc Prev (2017) 0.76
Biology of incretins: GLP-1 and GIP. Gastroenterology (2007) 10.45
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. N Engl J Med (2015) 6.48
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation (2008) 4.22
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med (2003) 3.57
Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol (2009) 3.43
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med (2011) 3.31
GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab (2006) 3.28
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem (2002) 3.08
Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab (2013) 2.60
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest (2002) 2.54
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology (2012) 2.48
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care (2010) 2.45
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
Control of human embryonic stem cell colony and aggregate size heterogeneity influences differentiation trajectories. Stem Cells (2008) 2.34
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology (2010) 2.33
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med (2013) 2.31
International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25
The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell (2005) 2.19
Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe (2013) 2.14
Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab (2007) 2.12
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest (2004) 2.11
Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol (2008) 2.03
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest (2005) 2.01
Plasma membrane calcium ATPase overexpression in arterial smooth muscle increases vasomotor responsiveness and blood pressure. Circ Res (2003) 1.99
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest (2006) 1.96
Modulation of taste sensitivity by GLP-1 signaling. J Neurochem (2008) 1.89
Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes (2006) 1.83
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol (2009) 1.79
A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res (2005) 1.76
Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci (2003) 1.74
Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology (2009) 1.74
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med (2013) 1.72
Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology (2005) 1.71
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes (2010) 1.71
Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest (2002) 1.70
Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice. Circulation (2006) 1.69
Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes (2013) 1.64
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes (2009) 1.62
Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. Biotechnol Bioeng (2009) 1.61
Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Cardiovasc Res (2011) 1.59
The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab (2008) 1.58
Clinical decisions. Management of type 2 diabetes. N Engl J Med (2008) 1.58
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept (2005) 1.57
Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes (2003) 1.55
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology (2004) 1.53
Growth differentiation factor 5 regulates cardiac repair after myocardial infarction. J Am Coll Cardiol (2010) 1.51
Sepsis-induced myocardial depression is associated with transcriptional changes in energy metabolism and contractile related genes: a physiological and gene expression-based approach. Crit Care Med (2010) 1.50
Serum-free differentiation of functional human coronary-like vascular smooth muscle cells from embryonic stem cells. Cardiovasc Res (2012) 1.47
The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy. J Am Coll Cardiol (2011) 1.46
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology (2007) 1.45
The Janus faces of iNOS. Circ Res (2003) 1.43
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology (2010) 1.42
beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes (2005) 1.41
A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation (2012) 1.39
Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation (2002) 1.39
Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes (2007) 1.39
Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circ Res (2005) 1.37
Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes (2012) 1.29
Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation (2005) 1.28
Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology (2003) 1.28
Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest (2011) 1.27
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes (2003) 1.26
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology (2008) 1.26
An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology (2008) 1.26
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology (2011) 1.25
Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes (2007) 1.24
GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol (2007) 1.24
Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes (2008) 1.24
Glucagon-like Peptide-2. Annu Rev Nutr (2006) 1.22
Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes (2008) 1.22
Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation (2004) 1.22
Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology (2007) 1.20
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest (2011) 1.20
Cytokines tumor necrosis factor-α and interferon-γ induce pancreatic β-cell apoptosis through STAT1-mediated Bim protein activation. J Biol Chem (2011) 1.20
ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology (2009) 1.17
Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes (2012) 1.17
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol (2013) 1.16
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am J Physiol Regul Integr Comp Physiol (2014) 1.16
Conditional expression of a dominant-negative c-Myb in vascular smooth muscle cells inhibits arterial remodeling after injury. Circ Res (2003) 1.16
Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology (2009) 1.15
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab (2008) 1.15
Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann N Y Acad Sci (2009) 1.12
Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes (2011) 1.10
The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology (2008) 1.10
Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes (2009) 1.10
The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology (2004) 1.09
Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes (2013) 1.09
The role of NOS in heart failure: lessons from murine genetic models. Heart Fail Rev (2002) 1.08
Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med (2006) 1.07
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev (2014) 1.06